<scp>SHP2</scp> inhibition displays efficacy as a monotherapy and in combination with <scp>JAK2</scp> inhibition in preclinical models of myeloproliferative neoplasmsGarima Pandey, Gary W. Reuther|American Journal of Hematology|2024Cited by 4